Premium
Involvement of the PlGF/VEGFR1 pathway in diabetes and type 1 retinal telangiectasia
Author(s) -
Kowalczuk Laura
Publication year - 2019
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2019.8133
Subject(s) - placental growth factor , medicine , diabetic retinopathy , macular telangiectasia , retinal , vascular endothelial growth factor , kinase insert domain receptor , vascular permeability , cancer research , vegf receptors , vascular endothelial growth factor a , endocrinology , diabetes mellitus , ophthalmology , fluorescein angiography
Among all the factors implied in the angiogenic balance, the vascular endothelial growth factors (VEGF) superfamily and their receptors (VEGFR) play a decisive role in microvascular permeabilization, as well as in neovascularization. It is well known that VEGF‐A promotes vascular permeability through VEGFR‐1 binding and activates cell proliferation through VEGFR‐2 binding. However, its homologous, placental growth factor (PlGF), specifically binds to VEGFR‐1 but not to VEGFR‐2. A number of studies have examined the role of PlGF in vascular retinal diseases and suggested that the PlGF‐ VEGFR‐1 pathway is involved in microvascular permeabilization and in telangiectasia. This presentation will focus on its role in diabetic retinopathy and in macular telangiectasia type 1.